Study to Evaluate the Safety and Efficacy of Switching From Zoladex® Monthly or Quarterly, to Eligard® Semiannual. (PRIZE)

PRospective, Multicenter Study to Evaluate Safety and Efficacy of Switching Treatments of Prostate Cancer Patients, Initially on Use of Monthly or Quarterly Goserelin Acetate (Zoladex®), to Semiannually Leuprorelin Acetate (Eligard®)

The purpose of this study is to evaluate the efficacy, quality of life and safety of switching from monthly (3.6 mg) or quarterly (10.8 mg) goserelin acetate (Zoladex®) to semiannual leuprorelin acetate 45 mg (Eligard® 45 mg) in prostate cancer patients with adequate hormonal castration level (plasma testosterone levels ≤50 ng/dL).

Study Overview

• Status: Completed
• Conditions: Prostate Cancer
• Intervention / Treatment: Drug: Leuprorelin Acetate (Eligard® 45 mg).

Detailed Description

When systemic treatment is indicated, androgen deprivation therapy is the standard treatment for patients with prostate cancer. This condition occurs when the patient is diagnosed with metastatic disease or disseminated disease based on PSA values.The exchange of androgen hormone deprivation therapies in patients with metastatic prostate cancer may be required in different situations in clinical practice, such as: lack of medication available at the institution or on the market; alteration of the clinical protocol of the health institution due to economic factors and/or aiming to gain adherence to the treatment, often related to the posological convenience and/or logistics necessary for the administration of the medication, among others.

Additionally, although there is evidence on the efficacy and safety of switching hormone treatments in patients with prostate cancer clinical data on this type of management of patients in Brazil are scarce. There are no data on how the management and switching of treatments is approached, nor on the clinical outcomes related to such a switch of therapy (time to progression, treatments used in combination with androgen deprivation therapy, time to onset of disease symptoms, time to start chemotherapy and costs involved).

• Study Type: Interventional
• Enrollment (Actual): 48
• Phase: Phase 4

Contacts and Locations

Study Locations

• Brazil
  • São Paulo, Brazil
    • IAMSPE - Instituto de Assistência Médica ao Servidor Público Estadual de S. Paulo
  • RS
    • Porto Alegre, RS, Brazil
      • CPMEC - Hospital Nossa Senhora da Conceição
  • SP
    • Barretos, SP, Brazil
      • HCB - Hospital do Câncer de Barretos
    • Jaú, SP, Brazil
      • Hospital Amaral Carvalho
    • São José do Rio Preto, SP, Brazil
      • CIP - Centro Integrado de Pesquisa
    • São Paulo, SP, Brazil
      • Icesp - Instituto Do Câncer Do Estado de São Paulo

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

1. Patient able to understand the process of the informed consent form (ICF);
2. Male aged ≥18 years old;
3. Having a histologically confirmed diagnosis of prostate adenocarcinoma;

4. Having an indication of androgen deprivation treatment:

   1. Being on treatment with monthly or quarterly goserelin acetate depot formulation for at least 3 months and for a maximum of 18 months OR;
   2. Having an indication to start treatment with quarterly goserelin acetate depot formulation.
5. Patient with ECOG (Eastern Cooperative Oncology Group) performance status 0 to 2;
6. Patient with appropriate castration level, defined by a serum testosterone level ≤50 ng/dL (≤1.73 nmol/L) demonstrated before V1.
7. Appropriate hematologic function in the screening period: neutrophil count >1,500/μL, platelets >100,000/μL, hemoglobin >10 g/dL;
8. Appropriate liver function in the screening period of the study: total serum bilirubin ≤1.5 x upper normal limit, AST (aspartate aminotransferase) or ALT (alanine aminotransferase) ≤40 U/L, alkaline phosphatase <130 U/L, gamma-GT (glutamyl transferase) <100 U/L;
9. Appropriate kidney function in the screening period of the study: serum urea within normal limits for the method used at the institution, serum creatinine between 0.6 and 1.3 mg/dL, creatinine clearance calculated by the Cockroft- Gault formula > 40 mL/min;

Exclusion Criteria:

1. Patients who did not have or do not have an indication for treatment with goserelin acetate;
2. Patients with goserelin treatment for over 18 months;
3. Patients who have received previous chemotherapy;
4. Patient unable to follow the foreseen study visit schedule;
5. Suspected or proven brain metastasis or active leptomeningeal disease;
6. Uncontrolled arterial hypertension defined as systolic pressure ≥160 mmHg or diastolic pressure ≥95 mmHg;
7. Long-term use of estrogen therapy or peripheral blockade;
8. Another concomitant neoplasm;
9. Any medical condition which, at the investigator's discretion, offers risk to the patient's participation in the study;
10. Having participated in another clinical study within less than 12 months.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Leuprorelin Acetate (Eligard® 45 mg); Patients received two subcutaneous injections of Eligard® 45 mg (leuprorelin acetate), with the first injection given at baseline (Visit 1) and the second after 168 ± 3 days at Visit 4.	Drug: Leuprorelin Acetate (Eligard® 45 mg).; Semiannually Leuprorelin Acetate (Eligard® 45 mg).; Other Names: Leuprorelin Acetate

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Baseline testosterone levels (≤50 ng/dL)	Maintenance of baseline testosterone levels (≤50 ng/dL) after switching from goserelin acetate to leuprorelin acetate 45 mg (Eligard® 45 mg, Zodiac).	One year of treatment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Efficacy (consecutive PSA > 4 ng/mL)	Disease progression rate from visit 2, defined as 3 consecutive elevations of PSA levels (with PSA > 4 ng/mL) and/or new clinical evidence of disease.	One year of treatment
Adverse events frequency (%)	Collection and descriptive analysis of adverse events.	One year of treatment
Number of Participants With Abnormal Laboratory Values (Number of participants)	Determination of the number of participants with abnormal laboratory values defined at discretion of the principal investigator according to reference values. Evaluation of hematologic, kidney and liver function.	One year of treatment
Number of Participants With Abnormal Vital Signs (Number of participants)	Determination of the number of participants with abnormal vital signs defined at discretion of the principal investigator, according to reference values. Evaluation of vital signs (e.g. electrocardiogram, blood pressure, pulse)	One year of treatment
Number of Participants With Abnormal Parameters for Quality of Life according to EORTC QLQ-C30 (Number of Participants)	Determination of the number of participants with abnormal parameters for quality of life at discretion of the principal investigator. Quality of life was evaluated using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)	One year of treatment
Number of Participants With Abnormal Parameters for Quality of Life according to EORTC QLQ-PR25 (Number of participants)	Determination of the number of participants with abnormal parameters for quality of life at discretion of the principal investigator. Quality of life was evaluated using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-PR25)	One year of treatment

Collaborators and Investigators

• Sponsor: Zodiac Produtos Farmaceuticos S.A.
• Investigators: Principal Investigator: Rafael Ferreira Coelho, Icesp - Instituto Do Câncer Do Estado de São Paulo

Study record dates

Study Major Dates

• Study Start (Actual): November 14, 2017
• Primary Completion (Actual): June 15, 2018
• Study Completion (Actual): June 15, 2020

Study Registration Dates

• First Submitted: March 11, 2022
• First Submitted That Met QC Criteria: March 21, 2022
• First Posted (Actual): March 31, 2022

Study Record Updates

• Last Update Posted (Actual): March 31, 2022
• Last Update Submitted That Met QC Criteria: March 21, 2022
• Last Verified: March 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Genital Neoplasms, Male; Prostatic Diseases; Prostatic Neoplasms; Physiological Effects of Drugs; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Reproductive Control Agents; Fertility Agents, Female; Fertility Agents; Leuprolide
• Other Study ID Numbers: 1500100

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No